Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zeo ScientifiX ( (ZEOX) ) has shared an update.
On June 24, 2025, ZEO ScientifiX announced the ZEO Masterclass, aimed at educating Florida physicians about the upcoming SB-1768 law effective July 1, 2025. This law allows MDs and DOs to offer non-FDA-approved stem cell therapies under strict compliance, impacting specialties like pain management and orthopedics. The masterclass will provide training on legal compliance, clinical integration, and ethical guidelines, positioning ZEO as a leader in regenerative medicine and supporting physicians in adopting new therapeutic solutions.
More about Zeo ScientifiX
ZEO ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutics. The company is committed to advancing regenerative medicine and biologic therapeutics, offering proprietary products like Zofin™ and Patient Pure X™. ZEO operates an FDA-registered, cGMP-compliant laboratory and has recently launched a collaborative product for hair regrowth.
Average Trading Volume: 5,900
Technical Sentiment Signal: Buy
Current Market Cap: $15.29M
See more data about ZEOX stock on TipRanks’ Stock Analysis page.